In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Citi analyst Mathieu Chevrier maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$345.00. The ...

These high quality options have been given the thumbs up by analysts. The post Buy CSL and these quality ASX 200 stocks now ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

“Accumulus Synergy is a catalyst for change. Leading with purpose and vision, Accumulus is not merely innovating but pioneering an industry paradigm shift for regulatory harmonization and digital ...

With reporting season all done and dusted for FY24, which ASX shares do our Foolish writers think came out on top? The post ...

Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...

This year’s bootcamp, taking place in Philadelphia on November 2nd, th, and 16th, is hosted and staffed by CSL. CSL is a global biotechnology leader that develops and delivers innovative lifesaving ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new ...

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that affects motor neurons. The average life ...

Despite the availability of evidence-based treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), their use frequently results in incomplete recovery.1 Intravenous ...